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Objective. To evaluate the relationship between adiponectin and physical activity (PA) in minority female youth. Methods. Plasma
adiponectin was measured in 39 females (mean age 9.2 ± 0.9 years; 30 Latina, 9 African-American; 56% overweight). PA was
assessed by accelerometry. Mean minutes per day spent in daily PA (DPA) (≥3 metabolic equivalents (METs)), moderate PA
(MPA)(4–7 METs), vigorous PA (VPA)(≥7 METs), and moderate-to-vigorous PA (MVPA)(≥4 METs) were calculated. The
association between adiponectin and PA, controlling for age, fat weight, lean weight, and insulin sensitivity (SI) was analyzed using
linear regression. Results. Adiponectin correlated with fat weight (r = −0.43, P < .01) and SI (r = 0.52, P < .01). Minutes spent
in DPA (β = −0.40, P = .02), MPA (β = −0.36, P = .04), or MVPA (β = −0.37, P = .03) were predictors of adiponectin in the
adjusted model. Conclusions. Higher PA levels were related to lower adiponectin levels. Potential mechanisms include upregulation
of adiponectin receptors or an increase in high-molecular weight adiponectin with increasing PA.
1. Introduction
Adiponectin is a protein that is secreted by adipose tissue.
Unlike other adipose-derived hormones such as leptin,
adiponectin levels decrease with increasing body mass index
(BMI) and are lower in obese individuals [1]. High levels
of adiponectin could be beneficial because adiponectin pro-
motes insulin sensitivity and has anti-inflammatory eﬀects
[2]. Physical activity (PA) may increase levels of adiponectin;
however, results are mixed (for a review, see [3]).
An increasing number of children in the United States
are overweight or obese, particularly in minority populations
[4]. Adiponectin levels are lower in overweight or obese
children compared to normal weight counterparts, and
males generally have lower adiponectin levels than females
[5]. Low levels of adiponectin can be a predictor of health
outcomes such as cardiovascular disease, cancer, and type 2
diabetes in adults [6–8], and consequently low adiponectin
levels during childhood or adolescence could have negative
long-term health eﬀects.
In children and adolescents, studies have reported
increases [9, 10], no change [11, 12], or decreases [13, 14] in
adiponectin with increasing PA. In a small study evaluating a
12-week combined diet and physical activity intervention in
15 obese adolescents, the intervention resulted in increased
adiponectin levels and decreased percent body fat [9].
However, the study involved a combined intervention and
the eﬀect of the decrease in body fat on adiponectin levels was
not taken into account. Likewise, a study of 26 obese Korean
adolescents showed an increase in adiponectin following
a 6-week jump rope intervention, without adjusting for
decreases in body fat [10]. Other studies report no rela-
tionship between PA and adiponectin in children and ado-
lescents, including a large cross-sectional study of French-
Canadian youth using a self-reported measure of PA [11]
and a 12-week PA intervention involving supervised physical
activity three times a week in overweight Greek adolescents
[12]. Interestingly, a study of mainly Caucasian children
in England aged 5–8 years found that adiponectin levels
decreased with increasing PA measured by accelerometry,
independent of percent body fat and that this eﬀect was
stronger in females than males [13]. An additional study in
adolescents using an activity questionnaire found a trend
towards decreased adiponectin with increasing PA [14].
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The direction of the relationship between adiponectin
and PA thus remains unclear, and the strength of the rela-
tionship may diﬀer by gender [13]. In addition, no studies
have examined the relationship between physical activity
and adiponectin levels in minority children, although one
study did find a relationship between increased physical
fitness (measured by VO2max) and decreased adiponectin in
Hispanic and Asian-American children [15]. The purpose
of this study was to evaluate if adiponectin levels are
associated with PA measured by accelerometry independent
of adiposity in Latina and African-American female youth.
2. Methods
2.1. Participants. Participants were members of the TRAN-
SITIONS Study, a longitudinal study of psychosocial and
physiological determinants of PA in Latina and African-
American females during the pubertal transition. Partici-
pants included in this study were those who had completed
their first annual visit in the TRANSITIONS Study by June
2009 and had accelerometry and adiponectin data from that
visit. TRANSITIONS participants were recruited from Los
Angeles County through participating physicians and clinics,
churches, schools, and community centers. Inclusion criteria
were: female gender, Tanner stage 1 or 2, nonmenstruating,
between the ages of 8 and 11, and Hispanic or African-
American ethnicity (both parents and all four grandparents
were Hispanic (Mexican or Central American) or African-
American). Participants were also required tomeet one of the
following criteria: (1) age- and gender-specific BMI ≥ 85th
percentile of the Centers for Disease Control and Prevention
(CDC) reference data [16], (2) one overweight parent (BMI
≥ 25), or (3) one parent with diagnosed diabetes. Exclusion
criteria were intake of medications known to influence body
composition, insulin action, or insulin secretion, meeting
diagnostic criteria for diabetes (assessed by fasting plasma
glucose ≥ 126mg/dL during a screening visit), or a previous
diagnosis of a major illness or disease. Parents and children
were provided with detailed written and verbal information
about the study in their primary language and informed
written consent from the parent and assent from the child
was obtained. The study was approved by the Institutional
Review Board of the University of Southern California
(USC).
2.2. Study Procedures. All procedures took place during
an overnight visit to the USC General Clinical Research
Center (GCRC). Upon arrival to the GCRC at approximately
13:00, participants and their parents were asked to complete
demographic and psychosocial questionnaires. Afterwards a
licensed pediatric health care provider performed a complete
medical examination and health history on the participant,
including verification of Tanner stage. Participants were
given a standardized dinner and a snack before 20:00
and were instructed to refrain from food or drink other
than water after 20:00. Participants spent the night in the
GCRC and the overnight fast was verbally verified with the
participant and parent in the morning. At 08:00, a fasting
blood draw was completed and followed by initiation of
the frequently sampled intravenous glucose tolerance test
(FSIVGTT). At time 0, glucose (25% dextrose, 0.3 g/kg body
weight) was administered intravenously. Blood samples were
collected at time points −15, −5, 2, 4, 8, 19, 22, 30, 40, 50,
70, 100, and 180minutes. Insulin (0.02 units/kg body weight,
Humulin R (regular insulin for human injection); Eli Lilly,
Indianapolis, IN) was injected intravenously at 20 minutes.
Following completion of the FSIVGTT, participants were
given lunch and completed measures of body composition.
At discharge, participants were provided with an accelerom-
eter, instructed on how to wear it, and asked to wear the
accelerometer for the ensuing 7 days. Participants were called
several times during the week to remind them to wear their
accelerometer. At the end of the week, study staﬀ retrieved
the accelerometer from participant’s homes.
2.3. Anthropometric Measurements. Weight and height were
measured three times to the nearest 0.1 kg and 0.1 cm,
respectively, using a beam medical scale and wall-mounted
stadiometer. The mean of the three measurements was
used to calculate BMI and BMI percentiles for age and
gender using publicly available SAS syntax from CDC (avail-
able at: http://www.cdc.gov/nccdphp/dnpa/growthcharts/
resources/index.htm). Children were classified as overweight
(including obese) if they had an age- and gender-specific
BMI ≥ 85th percentile of the CDC reference data [16].
Total body composition was measured by air displacement
plethysmography (BodPod; Life Measurement Instruments,
Concord, CA). This system uses computerized pressure
sensors to determine body volume and body density through
air displacement. BodPod provides an accurate measure of
body fat and lean body mass in children without dunking,
pinching, exposure to electric currents, or radiation, and
has been validated in children against hydrostatic weighing,
dual energy X-ray absorptiometry (DEXA), and multi-
compartment models [17, 18].
2.4. Clinical Measurements. Fasting blood samples were
assayed for adiponectin, insulin, and glucose. All samples
were collected in vacutainer tubes and stored on ice until
centrifugation, after which plasma was separated and stored
at −80◦C until analysis. Adiponectin concentration (μg/ml)
was measured with an enzyme-linked immunosorbent assay
(ELISA) kit (Millipore, St. Charles, MO). The intra- and
interassay coeﬃcients of variation (CV) were 7.4% and 8.4%,
respectively. Insulin was measured with an ELISA (Millipore,
St. Charles, MO). Glucose was measured on-line with an
automated glucose analyzer (Yellow Springs Instrument,
Yellow Springs, OH) using the glucose oxidase method. All
samples were assayed in duplicate.
The results of the FSIVGTT were used to determine
insulin sensitivity (SI) and acute insulin response to glucose
(AIRg) using the minimal model [19] (MINMOD MIL-
LENIUM 2002 computer program, Version 5.16; Richard
Bergman, Los Angeles, CA [20]). Insulin sensitivity is a
measure of insulin-stimulated glucose uptake and AIRg
characterizes the first phase of insulin secretion after glucose
administration.
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2.5. Accelerometry. A biaxial accelerometer (Actigraph
GT1M, Pensacola, FL) was used to objectively measure
physical activity. Participants were instructed to wear
the device on their right hip during waking hours (with
the exception of time spent in bathing or swimming
activities) for the 7 days immediately following the visit
to the GCRC. The accelerometers collected data in 15-
second epochs and the data were aggregated to 60-second
epochs for use with the current activity cut points. Data
was visually inspected for monitor malfunction (i.e., the
monitor got wet) and improper wear (i.e., the participant
wore the accelerometer overnight while sleeping) prior
to data processing. Data processing was done using SAS
9.2. Minutes of wear and nonwear were calculated using
a modification of a publicly available program (available
at: http://www.riskfactor.cancer.gov/tools/nhanes pam).
Participants with <4 days of wear (10 hour/day) were
asked to wear the accelerometer for an additional 7
day period. Data from the second wear was combined
with that from the first wear to ensure suﬃcient days of
wear.
Accelerometer data is presented as mean counts per
minute (cpm) and as estimates of mean minutes spent in
various activity levels. Mean cpm was calculated by dividing
the total counts per day by the total minutes of wear per
day. Mean minutes in the activity levels was calculated
by summing each minute spent above the user-defined
thresholds for moderate PA (MPA), vigorous PA (VPA),
and moderate-to-vigorous PA (MVPA) and below the user-
defined threshold for sedentary behavior (SB). The cut-
points for MPA and VPA were 4 and 7 metabolic equivalents
(METs), respectively, cut points which have been proposed
for children between the ages of 6 and 17 years [21]. In
addition, daily PA (DPA) was assessed using a lower cut
point (3 METs) [22] to capture a wider range of PA as
well as to be comparable to studies using 3 METs as the
cut point for MPA. The sedentary cut point was ≤100
counts/minute [23] and has been validated in adolescents
[24].
2.6. Statistical Analyses. Comparisons were made using
chi-square for comparisons of diﬀerences in frequency
(categorical variables), Student’s t-test for comparison of
means (continuous variables), and Pearson’s correlation
coeﬃcient for linear correlations. Nonnormally distributed
variables were log-transformed for use in linear correlation
analysis. Several multiple linear regression analysis were
performed to determine whether the association between
adiponectin (dependent variable) and physical activity levels
(independent variable) was significant after adjustment for
the potential confounding factors of age, fat weight, lean
weight, and SI. The potential confounders of age, fat weight,
lean weight, and SI were included in all models and separate
models were conducted for each physical activity variable
(mean counts per minute, mean minutes spent in SB, MPA,
VPA, MVPA, or DPA) to avoid multicolinearity caused by
entering all the PA variables into one model. Calculations
were done using SPSS 16.0 for Windows. Results were
considered significant at P < .05.
3. Results
3.1. Subject Characteristics. Table 1 shows the character-
istics of participants included in this study. Twenty-two
participants (56%) met criteria for overweight. When the
overweight classification criteria proposed by the Interna-
tional Obesity Taskforce (IOTF) were applied, results were
identical [25]. Of the 51 females who completed their first
annual visit for the TRANSITIONS Study by June 2009, the
39 participants (30 Latina, 9 African American) who had
an adiponectin measurement from that visit and at least
four days of valid accelerometry data were included in the
current analyses. The 12 excluded participants did not diﬀer
significantly from the included participants in terms of age,
ethnicity, BMI, fat weight, lean weight, or insulin sensitivity
(P > .40).
3.2. Adiponectin, Adiposity, and Insulin Sensitivity. Adi-
ponectin levels (mean 8.7±3.0μg/mL; range 1.1–14.0 μg/mL)
were normally distributed. Adiponectin did not diﬀer by
Tanner stage (Tanner 1,N = 20, adiponectin 9.4±2.9μg/mL;
Tanner 2, N = 19, adiponectin 8.0± 3.1μg/mL; P = .16), or
diﬀer by ethnicity (Latina, N = 30, 8.7± 3.0μg/mL; African-
American, N = 9, 8.8± 3.1μg/mL; P = .89).
Table 2 shows correlations between adiponectin and
anthropometric measures, clinical measures, and accelerom-
etry data. Adiponectin levels correlated negatively with BMI
(r = −0.41, P = .01) and fat weight (r = −0.43, P < .01) and
correlated positively with SI (r = 0.52, P < .01).
3.3. Relationship to Physical Activity and Sedentary Behavior.
Table 3 shows the results of linear regression analysis for
the outcome adiponectin. After adjusting for age, fat weight,
lean weight, and SI, mean counts per minute (β = −0.36,
P = .02), mean minutes spent in DPA (β = −0.40,
P = .02), mean minutes spent in MPA (β = −0.36,
P = .04), or mean minutes spent in MVPA (β = −0.37,
P = .03) were significant predictors of adiponectin levels.
The results for VPA (β = −0.28, P = .08) trended
towards significance. There was no association between
mean minutes spent in SB and adiponectin levels in the
adjusted model (β = 0.23,P = .13). Insulin sensitivity was
a significant predictor of adiponectin levels in all models
(P < .05).
Results were stratified by BMI percentile to explore if
the relationship between adiponectin and PA was diﬀerent
in nonoverweight versus overweight children. In participants
with BMIs ≥ 85th percentile (N = 22), after adjusting for
age, fat weight, lean weight, and SI, mean minutes spent in
DPA (β = −0.49, P = .04) was a significant predictor of
adiponectin levels. Mean minutes spent in SB (β = 0.06,
P = .81), MPA (β = −0.36, P = .12), VPA (β = 0.000,
P = 1.0), or MVPA (β = −0.33, P = .15) were not significant
predictors of adiponectin levels. In participants with BMIs <
85th percentile (N = 17), after adjusting for age, fat weight,
lean weight, and SI, mean minutes spent in DPA (β = 0.16,
P = .58), SB (β = 0.20, P = .34), MPA (β = 0.22, P = .48),
VPA (β = 0.19, P = 0.55), or MVPA (β = 0.26, P = 0.58)
were not significant predictors of adiponectin levels.
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Table 1: Subject characteristics (N = 39).
Variable
Anthropometric/Demographic Measures
Age (years) 9.2± 0.9
Ethnicity (% Latina) 77%
BMI (kg/m2) 21.9± 4.9
BMI percentile (CDC guidelines) 79.6± 23.8
BMI percentile ≥ 85% (overweight/obese; % meeting criteria) 56%
Fat weight (kg) 12.8± 8.6
Fat weight (% of total weight) 26.4± 10.9
Lean weight (kg) 31.0± 7.1
Clinical Measures
Adiponectin (μg/mL) 8.7± 3.0
Fasting insulin (μU/mL) 15.0± 13.0
Fasting glucose (mg/dL) 92.0± 5.2
Insulin sensitivity (SI) (×10−4 min−1/(μIU/mL)) 3.3± 2.0
Acute insulin response to glucose (AIRg) (μU/mL ×min) 1196± 882
Accelerometry
Days of valid wear 6.6± 2.5
Mean counts per minute 444± 156
Minutes/day spent in:
SB 417± 72
MPA (4–7 METs) 44± 24
VPA (≥7 METs) 4± 7
MVPA (≥4 METs) 48± 29
DPA (≥3 METs) 122± 47
Values shown are mean ± standard deviation
BMI: Body mass index, CDC: Centers for Disease Control and Prevention, METs: Metabolic equivalents, PA: Physical activity, SB: Sedentary behavior, MPA:
Moderate PA, VPA: Vigorous PA, MVPA: Moderate-to-vigorous PA, and DPA: Daily PA.
Table 2: Unadjusted correlations between adiponectin and anthropometric and clinical measures.
Variable r P-value
Anthropometric/Demographic Measures
Age (years) −0.21 0.20
BMI (kg/m2) −0.41 0.01∗
Fat weight (kg) −0.43 <0.01∗
Lean weight (kg) −0.26 0.11
Clinical Measures
Fasting insulin (μIU/mL)(log) −0.43 <0.01∗
Fasting glucose (mg/dL)(log) −0.34 0.03∗
Insulin sensitivity (SI) (×10−4 min−1/(μIU/mL)) 0.52 <0.01∗
Acute insulin response to glucose (AIRg) (μU/mL ×min) (log) −0.57 <0.001∗
Accelerometry
Mean counts per minute −0.04 0.81
Minutes/day spent in:
SB 0.09 0.58
MPA (4–7 METs) 0.02 0.89
VPA (≥7 METs) 0.02 0.89
MVPA (≥4 METs) 0.02 0.88
DPA (≥3 METs) −0.002 0.99
∗
P < .05.
BMI: Body mass index, METs: Metabolic equivalents, PA: Physical activity, SB: Sedentary behavior, MPA: Moderate PA, VPA: Vigorous PA, MVPA: Moderate-
to-vigorous PA, and DPA: Daily PA.
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Table 3: Linear regression for the outcome adiponectin levels controlling for age, fat weight, lean weight, and insulin sensitivity.
PA variable
Overall Model Physical Activity
R R2 P-value β∗∗ P-value
Mean counts per minute 0.66 0.44 <0.01∗ −0.36 0.02∗
Minutes/day SB 0.62 0.38 <0.01∗ 0.23 0.13
Minutes/day MPA (4–7 METs) 0.65 0.42 <0.01∗ −0.36 0.04∗
Minutes/day VPA (≥7 METs) 0.63 0.40 <0.01∗ −0.28 0.08
Minutes/day MVPA (≥4 METs) 0.65 0.43 <0.01∗ −0.37 0.03∗
Minutes/day DPA (≥3 METs) 0.66 0.44 <0.01∗ −0.40 0.02∗
∗
P < .05.
∗∗β coeﬃcients are standardized,
METs: Metabolic equivalents, PA: Physical activity, SB: Sedentary behavior, MPA: Moderate PA, MVPA: Moderate-to-vigorous PA, and DPA: Daily PA.
4. Discussion
Adiponectin levels correlated positively with SI and neg-
atively with measures of adiposity and AIRg in minority
female youth. The relationship between adiponectin and SI
has been shown previously using results from the oral glucose
tolerance test [12] and the homeostasis model assessment of
insulin resistance (HOMA-IR) [9, 11, 13, 14]. The measure
used here, frequently sampled intravenous glucose tolerance
test (FSIVGTT), allows for the estimation of SI as well as beta
cell functionality with AIRg. Lower acute insulin response
and higher insulin sensitivity may be related in part through
adiponectin because insulin can suppress adiponectin lev-
els [26] and adiponectin can increase insulin sensitivity
[2].
In linear regression models, more time spent in PA was
associated with significantly lower adiponectin levels. The
inverse association between PA and adiponectin is somewhat
surprising, but consistent with previous studies which have
shown a decrease in adiponectin with increasing PA [13,
14] or physical fitness [15]. It has been suggested that the
expression or secretion of adiponectin may be reduced by
PA-induced improvement in insulin action [27] or that
adiponectin levels are downregulated when physical activity
levels are suﬃcient to maintain insulin sensitivity [13].
Alternative mechanisms for such a relationship are upregu-
lation of adiponectin receptors or a shift in the amount of
adiponectin protein existing as the more biologically active
isoform, high-molecular weight (HMW) adiponectin, with
increasing PA.
Adiponectin has two receptors: Adiponectin receptor-1
(AdipoR1) and adiponectin receptor-2 (AdipoR2) [28].
Both of these receptors are expressed in human skeletal
muscle [29] and may play a role in the insulin-sensitizing
eﬀect of adiponectin [29, 30]. Higher levels of PA could lead
to an upregulation of the receptors for adiponectin, resulting
in a reduced need for high levels of circulating adiponectin.
While a single bout of exercise may either increase [30]
or decrease [31] AdipoR1 or AdipoR2 expression levels,
long-term exercise interventions appear to increase AdipoR1
and AdipoR2 expression levels in skeletal muscle [30, 32].
This could lead to a decrease in adiponectin protein levels,
as adiponectin receptor expression and adiponectin protein
levels may be inversely related [30]. However, changes
in adiponectin receptor expression levels are not always
accompanied by changes in circulating levels of adiponectin
protein [32]. Also, it is not known if changes in adiponectin
receptor expression level reflect membrane receptor
availability.
Rather than altering adiponectin receptors, PA could
change the amount of adiponectin existing as the more bio-
logically active isoform, high-molecular weight adiponectin.
Adiponectin exists as threemultimers: highmolecular weight
(HMW; >220 kilodaltons (kDa)), middle molecular weight
(MMW; ∼120 kDa), and low molecular weight (LMW;
∼70 kDa ) adiponectin [32]. TheHMW form of adiponectin
may be more biologically active and more tightly correlated
with insulin sensitivity than MMW or LMW [32], and
adiponectin isoform levels may be more informative than
the total amount of adiponectin [33]. Physical activity may
change the ratio of adiponectin multimer isoforms (decrease
MMW relative to HMW and LMW) [32], thereby increasing
the biological activity of adiponectin.
When results were stratified by weight status, the
association between adiponectin and PA was only seen
in those participants who were overweight (BMI ≥ 85th
percentile). Previous research has shown that AdipoR1
expression is higher in obese participants compared to lean
controls [34], and that AdipoR1 expression increased in the
muscle of obese, but not lean, rats after an 8-week moderate
exercise program [35]. Although this finding needs to be
replicated in larger studies, the inverse relationship between
adiponectin and PA may be stronger in overweight/obese
children because of adiponectin receptor expression
levels.
There was no significant association between SB and
adiponectin levels after adjustment for adiposity and SI. It
is possible that the mechanisms that regulate the decrease in
adiponectin with PA are not downregulated with increasing
SB. However, there was a slight trend towards an increase
in adiponectin with increasing SB in the linear regression
(β = 0.23, P = 0.13), which would support the hypothesis
that adiponectinmay be increased to compensate for a lack of
PA. This is the first study to evaluate the association between
adiponectin and SB and this relationship should be evaluated
further.
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This study has several strengths, including an objective
measure of physical activity, insulin sensitivity determined
by FSIVGTT, and participants from an understudied pop-
ulation. Limitations include the small sample size, cross-
sectional design which does not allow determination of
directionality between two variables particularly when they
both can alter over time, very low levels of vigorous
PA which makes it diﬃcult to examine the relationship
between VPA and adiponectin, and no measure of physical
fitness which could be a mediator of the relationship
between PA and adiponectin. In addition, studies of PA
and adiponectin receptors and isoforms were conducted in
adults, and it is unknown if the mechanisms outlined here
are applicable to children. These results may not generalize
to other populations, including male children, and should
be verified using a larger sample size and longitudinal
design.
Adiponectin is an important protein because of its
association with chronic diseases such as cardiovascular
disease, cancer, and diabetes. To the best of our knowledge,
this is the first study to examine the association between
PA and adiponectin levels in minority children and also
the first to examine the relationship between adiponectin
and SI as measured by FSIVGTT. Although small, this study
does cast doubt upon the hypothesis that adiponectin levels
increase with increasing levels of PA independent of changes
in body fat and proposes potential mechanisms for such
a relationship. Future studies may be able to clarify the
mechanism through which adiponectin and PA are related
and provide insight into the regulation of this important
adipose-derived hormone.
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